Review in Clinics in geriatric medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
6 authors.
Oliver M ToddAcademic Unit for Ageing and Stroke Research, University of Leeds, Leeds, LS2 3AA, United Kingdom; Bradford Institute for Health Research, Bradford Teaching Hospitals NHS Trust, Bradford BD9 6RJ, United Kingdom. Electronic address: o.todd@leeds.ac.uk.
Matthew KnightAcademic Unit for Ageing and Stroke Research, University of Leeds, Leeds, LS2 3AA, United Kingdom.
Joshua A JacobsIntermountain Healthcare Department of Population Health Sciences, Spencer Fox Eccles School of Medicine, University of Utah, Salt Lake City, UT 84112, USA. Electronic address: https://twitter.com/JoshJPharmD.
Catherine G DeringtonIntermountain Healthcare Department of Population Health Sciences, Spencer Fox Eccles School of Medicine, University of Utah, Salt Lake City, UT 84112, USA.
James P SheppardNuffield Department of Primary Care Health Sciences, University of Oxford, Oxford OX2 6GG, United Kingdom.
Adam P BressIntermountain Healthcare Department of Population Health Sciences, Spencer Fox Eccles School of Medicine, University of Utah, Salt Lake City, UT 84112, USA.
Funding
Informing optimal first-line antihypertensive therapy: A rigorous comparative effectiveness analysis of ARBs vs. ACEIs on long-term risk of dementia, cancer, heart disease, and quality of lifeR01AG074989 · NIA · UNIVERSITY OF PENNSYLVANIA · PI BRESS, ADAM P, COHEN, JORDANA B. · 2022 to 2025
$3.3M
Patient Level Prediction of Clinical Outcomes and Cost-Effectiveness in SPRINT (Optimize-SPRINT)R01HL139837 · NHLBI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI BRESS, ADAM P, MORAN, ANDREW EDWARD · 2018 to 2021
$3.2M
Guiding next steps for SPRINT-MIND implementation: Identifying high-benefit subgroups and comparative effects of ARB- vs. ACEI-based regimensR01AG065805 · NIA · UNIVERSITY OF UTAH · PI BRESS, ADAM P · 2020 to 2023
$2.7M
Using pharmacoepidemiology to optimize antihypertensive medication use to prevent aging-related multimorbidity: Midcareer investigator award in patient-oriented research and mentoring.K24AG080168 · NIA · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Adam P Bress · 2023 to 2026
$793k
British Heart Foundation FS/19/13/34235British Heart Foundation PG/21/10341NHLBI NIH HHS R01 HL139837NIA NIH HHS K24 AG080168NIA NIH HHS R01 AG065805NIA NIH HHS R01 AG074989Wellcome TrustWellcome Trust 211182/Z/18/Z
6 · The paper itself
Abstract
The authors conducted a review of pharmacologic therapy in older adults with hypertension. They reviewed the evidence supporting their use in older adults, understanding the physiologic changes and potential adverse drug effects associated with aging and antihypertensive medication use, exploring guideline recommendations for antihypertensive use in older adults, and evaluating the associated risks and benefits of specific classes of antihypertensive medications.
Indexed as
Antihypertensive AgentsHypertensionAgedAged, 80 and overAgingHumansPractice Guidelines as TopicAntihypertensive AgentsAged pharmacotherapyAntihypertensiveBlood pressureFrailtyHypertensionMultimorbidity
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Pharmacologic Treatment of Hypertension in Older Adults. · full record | OpenQuestion